Loading data
AGYSNasdaq
| Unit: USD | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 319.31 m USD | 275.62 m USD | 237.46 m USD | 198.07 m USD | 162.64 m USD |
| Cost of revenue | 119.39 m USD | 103.64 m USD | 93.21 m USD | 77.25 m USD | 61.1 m USD |
| Gross profit | 199.92 m USD | 171.99 m USD | 144.26 m USD | 120.82 m USD | 101.53 m USD |
| Research and development expense | 72.75 m USD | 62.41 m USD | 56.74 m USD | 50.26 m USD | 46.33 m USD |
| Selling, general and administrative expense | — | — | 128.5 m USD | 107.94 m USD | 95.21 m USD |
| Operating profit | 43.02 m USD | 22.59 m USD | 15.75 m USD | 12.88 m USD | 6.32 m USD |
| Interest expense | 493 k USD | 1.53 m USD | 0 USD | 0 USD | 12 k USD |
| Profit before tax | 48.41 m USD | 25.64 m USD | 20.68 m USD | 15.76 m USD | 6.51 m USD |
| Income tax expense | 9.62 m USD | 2.41 m USD | -65.51 m USD | 1.18 m USD | 33 k USD |
| Net income (reported basis) | 38.79 m USD | 23.23 m USD | 86.2 m USD | 14.58 m USD | 6.48 m USD |
| Net income attributable to common shareholders | 38.79 m USD | 23.23 m USD | 84.99 m USD | 12.75 m USD | 4.64 m USD |
| Basic earnings per share | 1.39 USD/share | 0.84 USD/share | 3.31 USD/share | 0.52 USD/share | 0.19 USD/share |
| Diluted earnings per share | 1.37 USD/share | 0.82 USD/share | 3.17 USD/share | 0.49 USD/share | 0.18 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.